Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
Prospective, randomized, placebo-controlled, double-blind part of the phase III trial to
assess the safety and efficacy of 4 weeks oxytocin (OT) administration on oral and social
skills in neonates/infants with Prader-Willi Syndrome (PWS) aged less than 3 months at
inclusion. Phase III clinical trial.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Toulouse
Collaborators:
Epidemiological and Clinical Research Information Network International Clinical Trials Association